Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Role of VAV2 in EGFR-mediated Rac1 responses in human prostate cancer

ABSTRACT: Role of VAV2 in EGFR-mediated Rac1 responses in human prostate cancer

PROVIDER: PRJNA1240273 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32808901_1.fastq.gz	Fastqsanger.gz
	SRR32808901_2.fastq.gz	Fastqsanger.gz
	SRR32808902_1.fastq.gz	Fastqsanger.gz
	SRR32808902_2.fastq.gz	Fastqsanger.gz
	SRR32808903_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Role of VAV2 in EGFR-mediated Rac1 responses in human prostate cancer

Project description:The small G-protein Rac1, a member of the Rho family of GTPases, is a central player in cancer progression and metastatic dissemination. Rac1 has been established as a bona fide effector of receptor tyrosine kinases, acting as a signaling node for growth factor-mediated responses such as motility, invasiveness, mitogenesis and gene expression. Previous studies demonstrated that Rac1 is aberrantly hyperactivated in aggressive cellular models of prostate cancer. Here we show that CRISPR-mediated knockout of Rac1 in prostate cancer cells leads to impaired proliferation and migration. Rac1-null cells display major alterations in gene expression, most notably affecting transcriptional programs associated with cell adhesion and extracellular matrix (ECM) regulation, but not those related to epithelial-to-mesenchymal (EMT) transition. Expression analysis of GEFs, the guanine nucleotide exchange factors responsible for Rac1 activation, followed by an unbiased RNAi screening, identified VAV2 as the foremost mediator of epidermal growth factor (EGF)-induced GTP loading onto Rac1 in prostate cancer cells. VAV2-deficient prostate cancer cells display significant proliferative and migratory defects, without noticeable changes in the expression of Rac1-regulated genes such as CDH1 and CDH3, indicating that VAV2 controls a discrete subset of Rac1-dependent responses. Finally, immunohistochemical assessment of VAV2 expression in human prostate specimens revealed significant VAV2 up-regulation in tumoral vs. non-tumoral areas. Our studies revealed important contributions of VAV2 to Rac1 activation in prostate cancer cells and highlight its potential prognostic value as a marker of prostate cancer progression.

2025-04-01 | GSE292590 | GEO

Kinase activity profiling shows osteoblast-induced EGFR/ERBB2 signaling in human androgen-sensitive prostate carcinoma cells

Project description:Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling

2009-04-02 | E-TABM-626 | biostudies-arrayexpress

Regulation of mevalonate pathway by Vav-Rac1 signaling favors breast primary tumorigenesis and lung metastasis

Project description:In the present study, we report that the expression of mevalonate pathway enzymes is mediated by the Rho guanosine nucleotide exchange factors Vav2 and Vav3 in a Rac1- and sterol regulatory element-binding factor-dependent manner in breast cancer cells. Furthermore, in vivo tumorigenesis experiments indicate that the two most upstream steps of this metabolic route (Hmgcs1, Hmgcr) are important for primary tumorigenesis, neoangiogenesis and cell survival in breast cancer cells. Hmgcr, but not Hmgcs1, is also important for the extravasation and subsequent fitness of breast cancer cells in the lung parenchyma. Genome-wide expression analyses revealed that Hmgcr influences the expression of gene signatures linked to proliferation, metabolism, and immune responses. The Hmgcr-regulated gene signature can predict long-term tumor recurrence but not metastasis in cohorts of non-segregated and chemotherapy-resistant breast cancer patients. The mevalonate pathway plays important roles in breast cancer and other tumor types. However, many issues remain obscure as yet regarding its mechanism of regulation and action.

2025-01-15 | GSE253308 | GEO

Transcriptome of K14 V12 Rac1 mice

Project description:Wholeskin from transgenic mice overexpressing epidermal specific (K14) activated mutant (V12) Rac1 analyzed with Illumina MouseRef8 v2 Gene Expression arrays Three V12 Rac1 7 day old pups compared to three 7 day old litter-mate controls

2016-06-13 | E-GEOD-71683 | biostudies-arrayexpress

Effect of Rac1 haploinsufficiency on the gene expression profile of mouse endothelial cells

Project description:The therapeutic potential of neurotrophic factors has been hampered by their inability to achieve adequate tissue penetration. Brain blood vessels, however, could be an alternative target for neuro-salvage therapies by virtue of their close proximity to neurons. Here we show that hemizygous deletion of Rac1 in mouse endothelial cells (ECs) attenuates brain injury and edema following focal cerebral ischemia. To explore the mechanisms whereby decrease of Rac1 in ECs provide neuroprotection, ECs were derived from Rac1+/+ and Rac1+/- mice. Microarray analysis was performed to determine the differential gene expression between Rac1+/+ and Rac1+/- ECs. Rac1+/+ and Rac1+/- ECs were cultured to subconfluence. Total RNA was extracted and reverse transcribed. Rac1+/+ (n = 2) and Rac1+/- (n = 2) EC cDNAs were labeled with Cy3 and Cy5, respectively, and equimolar mixtures of labeled Rac1+/+ and Rac1+/- probes were hybridized to 2 slides (sample #21648, #21649). Additionally, Rac1+/+ (n = 2) and Rac1+/- (n=2) EC cDNAs labeled with Cy5 and Cy3 (dye-swapping) were hybridized to 2 slides (sample #21650, #21651). Comparison of signal intensities between Rac1+/+ (channel 2) and Rac1+/- (channel 1) was conducted on each slide (sample), and the ratio of intensities from 4 slides were statistically assessed for each gene feature to investigate differential gene expression.

2009-03-15 | E-GEOD-15003 | biostudies-arrayexpress

Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer

Project description:Expression of HS3ST1 is markedly upregulated in castration-resistant prostate cancer, which proliferates hormone-independently. In a novel mechanism, EGFR–ERK1/2 signaling is activated via 3-O-sulfated HS and EGF/HB-EGF binding in castration-resistant prostate cancer.

2023-07-20 | GSE223471 | GEO

Interacting partners of Rac1 (P29S/Q61L) compared to constitutively active Rac1 (Q61L)

Project description:Interactors of double mutant Rac1 (P29S/Q61L) compared to constitutively active Rac1 (Q61L).

2019-11-12 | PXD013941 | Pride

Transcription profiling of rac1 knock-down zebrafish embryos

Project description:Phenotypic, proteome and transcriptome analysis of rac1 knockdown in zebrafish embryos

2008-12-31 | E-MEXP-1593 | biostudies-arrayexpress

Pseudomonas sp. RAC1

Project description:Pseudomonas sp. RAC1 Genome sequencing and assembly

| PRJNA1000279 | ENA

Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib

Project description:Non-small cell lung cancers (NSCLCs) harboring activating EGFR mutants show dramatic responses to EGFR TKIs, such as erlotinib and geffitinib. However, nearly all patients show relapse within 1 year after initial treatment. We used microarrays to detail global gene expression changes in EGFR mutant cells vs. WT cells responding to erlotinib. 4 EGFR mutant and 4 WT NSCLC cells were treated with or without erlotinib for 24 hr, followed by RNA extraction and hybridization on Affymetrix microarrays.

2014-05-16 | E-GEOD-57156 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data